Show/Hide Menu

Ylanthia®

The industry’s largest antibody Fab library to date uses a unique concept for the in vitro generation of highly specific and fully human antibodies. 

The antibody library has all the necessary prerequisites for selecting antibodies against all possible starting points of disease-relevant target molecules due to its structural range and diversity. If one can succeed in exhausting all of the possibilities for binding promising target molecules, this can result in unique product opportunities and compound candidates that can intervene at the crucial points in a disease process.

The antibody library has all the necessary prerequisites for selecting antibodies against all possible starting points of disease-relevant target molecules due to its structural range and diversity. If one can succeed in exhausting all of the possibilities for binding promising target molecules, this can result in unique product opportunities and compound candidates that can intervene at the crucial points in a disease process.Ylanthia takes antibody technology beyond current methods. A guiding principle underlying the design and construction of the Ylanthia library was to ensure that the library is of the highest possible quality. Features which distinguish Ylanthia from other technologies include:

  • Size and heavy/light chain pairing: Ylanthia is the industry’s largest known antibody Fab library, comprising over 100 billion distinct, fully human antibodies. Ylanthia uses 36 fixed, naturally-occurring heavy and light chain framework combinations, which translates into unprecedented structural diversity. Great care was invested into the antigen binding site design. The library’s diversity is expected to result in antibodies against previously inaccessible target molecules and unique epitope coverage.
  • Biophysical properties: Antibody frameworks were pre-selected for expression levels, stability and aggregation behavior. A shift towards higher stability and stress tolerance will increase shelf life and serum stability of resulting antibody-products, making them more cost-effective to produce and administer. A higher solubility in turn opens up the path for more convenient formulations for patients, such as subcutaneous administration.
  • Optimization: When needed, antibodies from the Ylanthia library are optimized using MorphoSys’s proprietary Slonomics® technology, which MorphoSys obtained through its 2010 acquisition of Sloning BioTechnology. Ylanthia thereby distinguishes itself in a central respect from HuCAL, which relies on a modular gene design and pre-formed cassettes for antibody optimization. Slonomics enables optimization of Ylanthia antibodies with unprecedented speed and flexibility.